Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG TEMPO PEN versus NOVOLOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG TEMPO PEN versus NOVOLOG.
HUMALOG TEMPO PEN vs NOVOLOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase and downstream signaling pathways.
Insulin analog that lowers blood glucose by binding to insulin receptors, enhancing peripheral glucose uptake, and inhibiting hepatic glucose production.
Subcutaneously, 0.2-0.5 units/kg within 15 minutes before or after a meal. Total daily dose is 0.5-1.0 units/kg.
Subcutaneous injection: 0.5-1 unit/kg/day divided into 3 or more doses given within 15 minutes before or after meals. Typical total daily dose range 0.5-1.5 units/kg.
None Documented
None Documented
1.0 hour (terminal elimination half-life); reflects rapid clearance of insulin lispro from circulation.
Terminal elimination half-life is 1.2-1.5 hours in healthy individuals, reflecting rapid clearance. In renal impairment (e.g., eGFR <30 mL/min), half-life may be prolonged up to 2-3 hours due to reduced degradation.
Renal: 100% of absorbed dose is eliminated via degradation, primarily in the liver and kidneys; no significant biliary/fecal excretion.
Renal excretion accounts for approximately 60-80% of insulin aspart degradation products; unchanged drug is minimally excreted. Biliary/fecal excretion is negligible (<10%).
Category C
Category C
Insulin Analog
Insulin Analog